These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8868446)

  • 21. Epitope mapping of monoclonal antibodies capable of neutralizing cytotoxic necrotizing factor type 1 of uropathogenic Escherichia coli.
    Meysick KC; Mills M; O'Brien AD
    Infect Immun; 2001 Apr; 69(4):2066-74. PubMed ID: 11254559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the human immune response to the UK anthrax vaccine.
    Baillie L; Townend T; Walker N; Eriksson U; Williamson D
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):267-70. PubMed ID: 15364114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mapping of antibody responses to the protective antigen of Bacillus anthracis by flow cytometric analysis.
    Reed DS; Smoll J; Gibbs P; Little SF
    Cytometry; 2002 Sep; 49(1):1-7. PubMed ID: 12210604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of the Bacillus anthracis 20 kDa protective antigen component.
    Hammamieh R; Ribot WJ; Abshire TG; Jett M; Ezzell J
    BMC Infect Dis; 2008 Sep; 8():124. PubMed ID: 18808698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a novel chimeric PA-LF antigen of Bacillus anthracis, its immunological characterization and evaluation as a future vaccine candidate in mouse model.
    Varshney A; Kumar M; Nagar DP; Pal V; Goel AK
    Biologicals; 2019 Sep; 61():38-43. PubMed ID: 31416791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin.
    Ezzell JW; Ivins BE; Leppla SH
    Infect Immun; 1984 Sep; 45(3):761-7. PubMed ID: 6432700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection.
    Vrentas CE; Moayeri M; Keefer AB; Greaney AJ; Tremblay J; O'Mard D; Leppla SH; Shoemaker CB
    J Biol Chem; 2016 Oct; 291(41):21596-21606. PubMed ID: 27539858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen.
    Chen Z; Moayeri M; Zhou YH; Leppla S; Emerson S; Sebrell A; Yu F; Svitel J; Schuck P; St Claire M; Purcell R
    J Infect Dis; 2006 Mar; 193(5):625-33. PubMed ID: 16453257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694.
    Laffly E; Danjou L; Condemine F; Vidal D; Drouet E; Lefranc MP; Bottex C; Thullier P
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3414-20. PubMed ID: 16048955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin.
    Little SF; Leppla SH; Cora E
    Infect Immun; 1988 Jul; 56(7):1807-13. PubMed ID: 3384478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.
    Price BM; Liner AL; Park S; Leppla SH; Mateczun A; Galloway DR
    Infect Immun; 2001 Jul; 69(7):4509-15. PubMed ID: 11401993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis.
    Kaur M; Chug H; Singh H; Chandra S; Mishra M; Sharma M; Bhatnagar R
    Mol Immunol; 2009 Jun; 46(10):2107-15. PubMed ID: 19356802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor.
    Singh Y; Klimpel KR; Arora N; Sharma M; Leppla SH
    J Biol Chem; 1994 Nov; 269(46):29039-46. PubMed ID: 7961869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
    Welkos S; Little S; Friedlander A; Fritz D; Fellows P
    Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses.
    Abdous M; Hasannia S; Salmanian AH; Shahryar Arab S; Shali A; Alizadeh GA; Hajizadeh A; Khafri A; Mohseni A
    Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):25-31. PubMed ID: 30621469
    [No Abstract]   [Full Text] [Related]  

  • 36. A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo.
    Singh Y; Chaudhary VK; Leppla SH
    J Biol Chem; 1989 Nov; 264(32):19103-7. PubMed ID: 2509473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Location of receptor-binding region of protective antigen from Bacillus anthracis.
    Little SF; Lowe JR
    Biochem Biophys Res Commun; 1991 Oct; 180(2):531-7. PubMed ID: 1953724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.
    Moayeri M; Leysath CE; Tremblay JM; Vrentas C; Crown D; Leppla SH; Shoemaker CB
    J Biol Chem; 2015 Mar; 290(10):6584-95. PubMed ID: 25564615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibody against the poly-gamma-D-glutamic acid capsule of Bacillus anthracis protects mice from enhanced lethal toxin activity due to capsule and anthrax spore challenge.
    Jang J; Cho M; Lee HR; Cha K; Chun JH; Hong KJ; Park J; Rhie GE
    Biochim Biophys Acta; 2013 Mar; 1830(3):2804-12. PubMed ID: 23201204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies.
    Varughese M; Chi A; Teixeira AV; Nicholls PJ; Keith JM; Leppla SH
    Mol Med; 1998 Feb; 4(2):87-95. PubMed ID: 9508786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.